Top Page
Chatham Rock Phosphate
(NZP)
Chatham Rock Phosphate (NZP) vs. iShares MSCI Canada ETF (EWC)
Chatham Rock Phosphate Business Overview & Revenue Model
Chatham Rock Phosphate Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 412.00 | 5.33K | 5.20K |
| Gross Profit | -30.71K | -33.92K | -37.52K | -3.65K | 2.16K | 5.20K |
| EBITDA | -1.01M | -1.22M | -1.44M | -1.52M | -1.03M | -569.50K |
| Net Income | -971.25K | -1.18M | -1.47M | -1.77M | -1.03M | -572.94K |
Balance Sheet | ||||||
| Total Assets | 6.94M | 6.88M | 6.96M | 7.85M | 8.13M | 5.22M |
| Cash, Cash Equivalents and Short-Term Investments | 23.97K | 35.21K | 110.17K | 820.38K | 1.37M | 378.87K |
| Total Debt | 21.49K | 29.41K | 57.73K | 87.05K | 0.00 | 0.00 |
| Total Liabilities | 528.59K | 400.13K | 408.34K | 578.82K | 1.05M | 85.41K |
| Stockholders Equity | 6.41M | 6.48M | 6.55M | 7.27M | 7.08M | 5.14M |
Cash Flow | ||||||
| Free Cash Flow | -930.53K | -1.27M | -1.67M | -1.59M | -888.38K | -840.37K |
| Operating Cash Flow | -804.05K | -1.14M | -1.52M | -1.50M | -802.87K | -767.55K |
| Investing Cash Flow | -109.41K | -109.41K | -155.29K | -94.05K | -164.50K | -72.83K |
| Financing Cash Flow | 768.41K | 1.18M | 1.02M | 1.11M | 2.01M | 1.17M |
Chatham Rock Phosphate Technical Analysis
Chatham Rock Phosphate Peers Comparison
Chatham Rock Phosphate Corporate Events
Chatham Rock Phosphate Limited has closed a previously announced non-brokered private placement, issuing 3,162,995 units at CAD $0.05 per unit for gross proceeds of CAD $158,150. Each unit comprises one common share and one transferable share purchase warrant exercisable at CAD $0.12 for 12 months, with an acceleration clause if the stock trades above CAD $0.20 for 20 consecutive days, and all underlying securities are subject to a hold period until April 24, 2026. The financing, which remains subject to final TSX Venture Exchange approval and carried no finder’s fees, will be used for general working capital, and included participation by company insiders treated as a related-party transaction under Canadian securities rules, though exempt from formal valuation and minority approval requirements because it did not exceed 25% of Chatham Rock’s market capitalization.
The most recent analyst rating on (TSE:NZP) stock is a Buy with a C$0.34 price target. To see the full list of analyst forecasts on Chatham Rock Phosphate stock, see the TSE:NZP Stock Forecast page.
Chatham Rock Phosphate has agreed to sell its wholly owned Australian subsidiary Avenir Makatea Pty Ltd to Austure Industries for AU$1.4 million, comprising AU$900,000 in staged cash payments over two years and a 20% stake in a new Austure subsidiary, Austure Phosphate AU Pty Ltd, which will build a DCP/MCP manufacturing plant in Cloncurry. The deal integrates Chatham’s Korella North rock phosphate as feedstock for an innovative, low-capex, modular plant that uses electricity rather than sulphuric acid to produce phosphoric acid, enabling domestic manufacture of feed phosphates in a market currently reliant on imports and facing high prices and supply constraints, particularly from China. The green process can use low-grade tailings from Korella North and produces a usable silica by-product, which, combined with proximity to northern Australian cattle markets, is expected to lower costs versus imports and bolster Australia’s sovereign capability in critical livestock nutrition inputs, while giving Chatham an ongoing strategic interest via its equity stake and board representation in the new venture.
The most recent analyst rating on (TSE:NZP) stock is a Buy with a C$0.34 price target. To see the full list of analyst forecasts on Chatham Rock Phosphate stock, see the TSE:NZP Stock Forecast page.
Chatham Rock Phosphate Limited has announced the granting of stock options to its directors, allowing them to purchase a total of 8,750,000 common shares at a price of CAD$0.054 per share. This move is part of the company’s Stock Option Plan and is expected to align the interests of the directors with those of the shareholders, potentially impacting the company’s governance and market perception.
The most recent analyst rating on (TSE:NZP) stock is a Buy with a C$0.34 price target. To see the full list of analyst forecasts on Chatham Rock Phosphate stock, see the TSE:NZP Stock Forecast page.
Chatham Rock Phosphate Limited has entered into a non-binding term sheet with an interested party to potentially acquire up to a 75% stake in the Chatham Rise Phosphate project through an earn-in program. This development marks a significant step for the company, as it aims to secure the necessary capital and partnerships to advance the project, potentially transforming its operational and financial landscape.
The most recent analyst rating on (TSE:NZP) stock is a Buy with a C$0.34 price target. To see the full list of analyst forecasts on Chatham Rock Phosphate stock, see the TSE:NZP Stock Forecast page.
Chatham Rock Phosphate Limited successfully concluded its 2025 Annual General and Special Meeting of Shareholders, with all management-recommended matters ratified. Key outcomes included the re-election of the board of directors, the re-appointment of Grant Thornton as auditors, and the approval of an amended Stock Option Plan, indicating strong shareholder support and strategic continuity.
The most recent analyst rating on (TSE:NZP) stock is a Buy with a C$0.34 price target. To see the full list of analyst forecasts on Chatham Rock Phosphate stock, see the TSE:NZP Stock Forecast page.
Chatham Rock Phosphate Limited has entered into a non-binding agreement to sell its subsidiary, Avenir Makatea Pty Ltd, to Austure Pty Ltd for AU$ 1.4 million. This deal includes a cash payment and a 20% stake in a new DCP/MCP manufacturing plant in Cloncurry, Australia. The plant will utilize Austure’s innovative technology to produce Dicalcium and Monocalcium phosphate, essential for cattle nutrition in Northern Australia. This development addresses previous challenges faced by Chatham in establishing a viable plant, such as scale and reliance on sulfuric acid, by using a novel green process that reduces costs and environmental impact. The agreement is expected to enhance Chatham’s market position by providing a local supply of phosphate products, potentially undercutting imported competitors.
The most recent analyst rating on (TSE:NZP) stock is a Buy with a C$0.34 price target. To see the full list of analyst forecasts on Chatham Rock Phosphate stock, see the TSE:NZP Stock Forecast page.
Chatham Rock Phosphate Limited is advancing its RailPhos project, which aims to connect the Korella North Mine to the Port of Karumba via a new railway line. The feasibility study for this project, led by Executive Director Colin Randall, has made significant progress, including engaging with landholders and inspecting existing rail infrastructure. The project is expected to enhance the company’s operational capabilities and strengthen its position in the phosphate industry.
The most recent analyst rating on (TSE:NZP) stock is a Buy with a C$0.34 price target. To see the full list of analyst forecasts on Chatham Rock Phosphate stock, see the TSE:NZP Stock Forecast page.
Chatham Rock Phosphate Limited has announced a non-brokered private placement to raise up to CAD 500,000 through the issuance of 10,000,000 units at CAD 0.05 per unit. Each unit includes a common share and a warrant, with the funds intended for general working capital. The private placement is subject to TSX Venture Exchange approval and is expected to close by December 5, 2025. This move could enhance the company’s financial flexibility and support its operational needs.
The most recent analyst rating on (TSE:NZP) stock is a Buy with a C$0.34 price target. To see the full list of analyst forecasts on Chatham Rock Phosphate stock, see the TSE:NZP Stock Forecast page.
Chatham Rock Phosphate Limited is actively pursuing financing options to advance its Chatham Rise project, with the potential for a partner to earn a significant ownership stake through capital contributions. The company is in exclusive negotiations with a credible marine mining investor, while also exploring short-term financial solutions to maintain operations and shareholder value amidst regulatory considerations.
The most recent analyst rating on (TSE:NZP) stock is a Buy with a C$0.34 price target. To see the full list of analyst forecasts on Chatham Rock Phosphate stock, see the TSE:NZP Stock Forecast page.
Chatham Rock Phosphate Limited has announced plans to supply rock phosphate to a new manufacturing plant in Cloncurry, Australia, which will produce Dicalcium Phosphate (DCP) and Monocalcium Phosphate (MCP) using a novel green technology. This development addresses previous challenges related to scale and sulfuric acid dependency, offering a scalable and economically viable solution that could out-price imported competitors, benefiting local cattle farmers and potentially enhancing the company’s market position.
The most recent analyst rating on (TSE:NZP) stock is a Buy with a C$0.34 price target. To see the full list of analyst forecasts on Chatham Rock Phosphate stock, see the TSE:NZP Stock Forecast page.